rheumatology
2016 ACR/EULAR Classification Criteria for Primary Sjögren's Syndrome
2016 ACR/EULAR criteria for classifying primary Sjögren's syndrome in patients with ocular or oral dryness (or positive anti-SSA). Score ≥4 = primary Sjögren's syndrome.
References
- Shiboski CH et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome. Arthritis Rheumatol. 2017;69(1):35–45.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Ianalumab (Anti-BAFF — Primary Sjögren's Syndrome) · Anti-BAFF Monoclonal Antibody (B-Cell Survival Factor Inhibitor)
- Pilocarpine · Muscarinic Agonist — Dry Mouth / Sjögren's
- Marstacimab · Anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody
- Natalizumab · Disease-Modifying Therapy — MS (Anti-VLA-4 Monoclonal Antibody)
- Inebilizumab (Anti-CD19 — IgG4-Related Disease) · Anti-CD19 Monoclonal Antibody (B-Cell Depleting)
- Trimetazidine · Metabolic Anti-Anginal
Pathways
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.